News
SRNE
--
0.00%
--
Sorrento Therapeutics files to sell ~851K shares from shareholder
Sorrento Therapeutics (SRNE) has filed to sell ~851K shares from selling shareholder Icahn School of Medicine at Mount Sinai.The proposed aggregate maximum offering price is ~$6.47M.Last month, Mount Sinai licensed
Seekingalpha · 1d ago
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (“Scilex”), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido® to ...
GlobeNewswire · 1d ago
DJ Sorrento Therapeutics' Subsidiary Gets FDA OK For Label Change to ZTlido
Dow Jones · 1d ago
Scilex Holding gets FDA sNDA approval for Ztlido label expansion
Scilex Holding, an over 99% owned subsidiary of Sorrento Therapeutics ([[SRNE]] -2.8%), has received a supplemental new drug application ((sNDA)) approval from the U.S. FDA for ZTlido to make efficacy
Seekingalpha · 1d ago
Sorrento Therapeutics Shares See Volume; Co Granted FDA Approval For Ztlido
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207962
Benzinga · 1d ago
Is Sorrento Stock a Buy Following ACEA Acquisition? Analyst Weighs In
TipRanks · 3d ago
Sorrento Inks Deal To Buy ACEA Therapeutics; Shares Gain 3%
Shares of Sorrento Therapeutics increased 3.3% to close at $8.27 on April 5 after the clinical-stage antibody-centric biopharmaceutical company agreed to snap up late-stage oncology company ACEA Therapeutics. Along with ACEA’s late clinical-stage drug Abiv...
SmarterAnalyst · 4d ago
Modus Advisors, LLC Buys Square Inc, Skyworks Solutions Inc, Baidu Inc, Sells JPMorgan Chase
GuruFocus News · 5d ago
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
GlobeNewswire · 5d ago
Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock
Benzinga · 5d ago
Sorrento Therapeutics To Buy ACEA Therapeutics For $38M In Stock
Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% royal...
Benzinga · 5d ago
Sorrento to acquire to acquire late-stage oncology company ACEA Therapeutics
Sorrento Therapeutics (SRNE) has agreed to acquire ACEA Therapeutics in return for $38M of its common stock.The milestone payments could add up to $450M in additional payments subject to certain
Seekingalpha · 5d ago
DJ Sorrento Therapeutics Buying ACEA Therapeutics
Dow Jones · 5d ago
Sorrento: ACEA Shareholders to Get up to $450 Million in Added Payments if Certain Milestones Met
Sorrento: ACEA Shareholders to Get up to $450 Million in Added Payments if Certain Milestones Met
Dow Jones · 5d ago
Sorrento To Acquire ACEA Therapeutics; ACEA Equity Holders To Receuve Up To $38M In Sorrento Common Stock, Sorrento To Pay ACEA Equity Holders Up To $450M In Additional Payments Upon Milestones
SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", , Sorrento", , )))) today announced the signing of a merger agreement pursuant to which Sorrento will acquire ACEA
Benzinga · 5d ago
Sorrento Therapeutics: ACEA Shareholders to Get up to $38 Million in Shares at Close
Sorrento Therapeutics: ACEA Shareholders to Get up to $38 Million in Shares at Close
Dow Jones · 5d ago
Sorrento Therapeutics to Buy ACEA Therapeutics >SRNE
Sorrento Therapeutics to Buy ACEA Therapeutics >SRNE
Dow Jones · 5d ago
Sorrento Enters Into Merger Agreement To Acquire Late-Stage Oncology Company ACEA Therapeutics >SRNE
Sorrento Enters Into Merger Agreement To Acquire Late-Stage Oncology Company ACEA Therapeutics >SRNE
Dow Jones · 5d ago
Press Release: Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
Dow Jones · 5d ago
New Strong Sell Stocks for March 31st
AROW, BGS, KEX, SRNE, and TOSYY have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2021
Zacks · 03/31 14:12
Webull provides a variety of real-time SRNE stock news. You can receive the latest news about Sorrento Thera through multiple platforms. This information may help you make smarter investment decisions.
About SRNE
Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.